 |
Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131 |
|---|---|
| Trade Name | Neuradiab |
| Orphan Indication | Primary malignant brain tumors |
| USA Market Approval | USA |
| USA Designation Date | 2005-10-04 00:00:00 |
| Sponsor | Bradmer Pharmaceuticals, Inc.;9900 Corporate Campus Drive, Suite 3000;Louisville, Kentucky, 40223 |
